Fourteen novel mucopolysaccharidosis IVA producing mutations in GALNS gene

被引:0
|
作者
Tomatsu, S
Fukuda, S
Cooper, A
Wraith, JE
Ferreira, P
DiNatale, P
Tortora, P
Fujimoto, A
Kato, Z
Yamada, N
Isogai, K
Yamagishi, A
Sukegawa, K
Suzuki, Y
Shimozawa, N
Kondo, N
Sly, WS
Orii, T
机构
[1] GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN
[2] UNIV MANCHESTER,ROYAL MANCHESTER CHILDRENS HOSP,SCH MED,MANCHESTER,LANCS,ENGLAND
[3] UNIV ALBERTA HOSP,DEPT PEDIAT,EDMONTON,AB T6G 2B7,CANADA
[4] UNIV NAPLES,DEPT BIOCHEM & BIOMED TECHNOL,NAPLES,ITALY
[5] UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,MILAN,ITALY
[6] USC,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,LOS ANGELES,CA
[7] CHUBU WOMENS COLL,SEKI,JAPAN
关键词
GALNS; SSCP; expression study; genotype/phenotype correlation; N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE GENE; MORQUIO-DISEASE; CLASSICAL MORQUIO; STEROID-SULFATASE; POINT MUTATIONS; CDNA; IDENTIFICATION; EXPRESSION; CLONING; PATIENT;
D O I
10.1002/(SICI)1098-1004(1997)10:5<368::AID-HUMU6>3.0.CO;2-B
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disorder caused by a deficiency of the lysosomal N-acetylgalactosamine-6-sulfate sulfatase, Here, we report our analysis of data on 21 patients of diverse ethnic and geographic origins studied by SSCP and sequencing analysis, Sixteen mutations were detected, including 14 new mutations (11 missense, one premature termination, one splice site alteration, and one cryptic site alteration), The donor splice site mutation (IVS4 + 1G-->A) predicts that normal splicing will be abolished and that translation would lead to an immediate premature termination (W141X), Another novel nucleotide change outside the coding sequence is an intronic alteration (IVS9-42C-->T:ggtcggtgcggttggtgc) creating a potential cryptic donor site, The nucleotide sequence surrounding this alteration is highly suggestive of a consensus donor splice site, All 12 missense and nonsense mutations were shown by transient expression to abolish or greatly reduce GALNS activity, thereby providing an explanation as to why they produce MPS IVA. All mutations were readily confirmed by restriction enzyme or by allelic specific oligonucleotide analysis (ASO), These findings, coupled with previously reported mutations, bring the total of different mutations to 41 among independent families with MPS IVA, illustrating the extensive allelic heterogeneity among mutations producing MPS IVA. (C) Wiley-Liss, Inc.
引用
收藏
页码:368 / 375
页数:8
相关论文
共 50 条
  • [21] In silico analysis of mutations occurring in the protein N-acetylgalactosamine-6-sulfatase (GALNS) and causing mucopolysaccharidosis IVA
    Tamarozzi, E. R.
    Torrieri, E.
    Semighini, E. P.
    Giuliatti, S.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) : 10025 - 10034
  • [22] Pharmacological chaperones as an alternative to increase GALNS activity in mucopolysaccharidosis type IVA
    Prada, Luisa
    Suarez, Diego A.
    Almeciga-Diaz, Carlos Javier
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 106 - 106
  • [23] MUCOPOLYSACCHARIDOSIS TYPE IVA - COMMON DOUBLE DELETION IN THE N-ACETYLGALACTOSAMINE-6-SULFATASE GENE (GALNS)
    HORI, T
    TOMATSU, S
    NAKASHIMA, Y
    UCHIYAMA, A
    FUKUDA, S
    SUKEGAWA, K
    SHIMOZAWA, N
    SUZUKI, Y
    KONDO, N
    HORIUCHI, T
    OGURA, S
    ORII, T
    GENOMICS, 1995, 26 (03) : 535 - 542
  • [24] Molecular basis of mucopolysaccharidosis type IVA (Morquio syndrome type A): A review and classification of GALNS gene variants and reporting of new variants
    Singh, Akashdeep
    Zanetti, Alessandra
    Morrone, Amelia
    Al-Sayed, Moeenaldeen
    Brusius-Facchin, Ana Carolina
    Chien, Yin-Hsiu
    D'Avanzo, Francesca
    Giugliani, Roberto
    Izzo, Emanuela
    Kasper, David C.
    Lin, Hsiang-Yu
    Lin, Shuan-Pei
    Pollard, Laura
    Tonin, Rodolfo
    Wood, Tim
    Tomanin, Rosella
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S101 - S101
  • [25] Investigation of GALNS variants and genotype-phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA
    Yi, Mengni
    Wang, Yu
    Gao, Xiaolan
    Han, Lianshu
    Qiu, Wenjuan
    Gu, Xuefan
    Maegawa, Gustavo H. B.
    Zhang, Huiwen
    JOURNAL OF INHERITED METABOLIC DISEASE, 2022, 45 (03) : 593 - 604
  • [26] Lentiviral gene therapy for mucopolysaccharidosis type IVA
    Celik, Betul
    Rintz, Estera
    Nidhi, Fnu
    Khan, Shaukat
    Tomatsu, Shunji
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 23 - 24
  • [27] MUCOPOLYSACCHARIDOSIS IVA - SCREENING AND IDENTIFICATION OF MUTATIONS OF THE N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE GENE
    OGAWA, T
    TOMATSU, S
    FUKUDA, S
    YAMAGISHI, A
    REZVI, GMM
    SUKEGAWA, K
    KONDO, N
    SUZUKI, Y
    SHIMOZAWA, N
    ORII, T
    HUMAN MOLECULAR GENETICS, 1995, 4 (03) : 341 - 349
  • [28] AAV Gene Therapy in Mucopolysaccharidosis IVA Murine Models
    Tomatsu, Shunji
    Sawamoto, Kazuki
    Stapleton, Molly
    Khan, Shaukat
    Bruder, Joseph T.
    Danos, Olivier
    Karumuthil-Melethil, Subha
    MOLECULAR THERAPY, 2020, 28 (04) : 579 - 580
  • [29] Heteroallelic missense mutations of the Galactosamine-B-Sulfate sulfatase (GALNS) gene in a mild form of Morquio disease (MPS IVA)
    Cole, DEC
    Fukuda, S
    Gordon, BA
    Rip, JW
    LeCouteur, AN
    Rupar, CA
    Tomatsu, S
    Ogawa, T
    Sukegawa, K
    Orii, T
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1996, 63 (04): : 558 - 565
  • [30] Adeno-associated virus vector combination gene therapy with C-type natriuretic peptide and GALNS enzyme in Mucopolysaccharidosis IVA mouse model
    Rintz, E.
    Celik, B.
    Khan, S.
    Wegrzyn, G.
    Tomatsu, S.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A204 - A204